glp·helper
glphelper.com/tirzepatide/colorado/parker
Dual GIP / GLP-1 receptor agonistFDA-approved May 2022 (Mounjaro) · November 2023 (Zepbound)Rx · Subcutaneous injection · Once weekly

Tirzepatide
(Mounjaro, Zepbound) in Parker, CO

Dr. Fahad Akhtar, M.D.
Medically reviewed by Dr. Fahad Akhtar, M.D.
Physician at g1v.me, an affiliated practice

Physicians near Parker, CO from the federal NPI registry. Ask each office whether it prescribes Mounjaro or Zepbound.[9]

  • Mounjaro: FDA-approved for type 2 diabetes.
  • Zepbound: FDA-approved for chronic weight management, and obstructive sleep apnea with obesity.
city providers
21
as of today

Same molecule (tirzepatide): Mounjaro in Parker, Zepbound in Parker

Other GLP-1 medicines: Ozempic in Parker, Wegovy in Parker, Semaglutide in Parker

§ 02Provider directory: Colorado
21 of 21 shown

Find a physician in Parker.

Every entry comes from the federal NPI registry. Ask each office what it prescribes. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Tirzepatide by Colorado town, physicians per town
§ 03Getting Tirzepatide in Parker
21 providers · Parker, CO

How to get Tirzepatide in Parker.

21 GLP-1 prescribers and 7 local resource types are on record for Parker, plus 3 nearby towns in the directory.

Physicians in Parker
21 physicians
21 physicians from the federal NPI registry in Parker, most listed as Family Medicine (10), Internal Medicine (9) and Physician Assistant (1). A licensed clinician who evaluates you decides whether an FDA-approved GLP-1 fits. Telehealth rules vary by state. The nearest towns on record are Castle Rock (21 providers), Centennial (23 providers) and Highlands Ranch (18 providers).
Around the prescription in Parker
7 listed nearby
29 dietitians, 4 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers, 6 physiotherapists and 5 places to move are on record near Parker.
Medicaid (weight loss)
Diabetes only
As of April 2026, Colorado Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Colorado’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

The molecule in Mounjaro and Zepbound. It acts on two gut-hormone pathways, GIP and GLP-1.

Tirzepatide is a once-weekly injection sold by Eli Lilly as Mounjaro (for type 2 diabetes) and Zepbound (for chronic weight management). It is the first approved dual GIP/GLP-1 receptor agonist. It activates two gut-hormone pathways rather than one, which is associated with greater average weight loss than single GLP-1 agonists.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% on placebo. In the SURPASS-2 head-to-head diabetes trial, tirzepatide produced larger HbA1c and weight reductions than semaglutide 1 mg.[1]

Bar chart of Tirzepatide dose strengths on the FDA label: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Tirzepatide comes in 6 strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg. The chart shows what the label lists. A prescriber sets the dose.[1]
At a glanceMultiple (brand-specific)
Active ingredient
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
May 2022 (Mounjaro) · November 2023 (Zepbound)
Approved use
Type 2 diabetes (Mounjaro) · chronic weight management (Zepbound)
Off-label use
Use outside the approved brand/indication is off-label
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Parker

Parker, Colorado has a population of 58,512 people. The adult obesity rate in Parker is an age-adjusted estimate of 25.1%, 0.1 percentage points above the Colorado state rate of 25%. Diagnosed diabetes reaches 6.2% of adults in Parker. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 14.1% of adults in Parker.

of Parker adults have obesity
25.1%
diagnosed diabetes
6.2%
no regular physical activity
14.1%

Age-adjusted estimates for Parker, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losshair shedding during weight loss
§ 05Support around Tirzepatide in Parker
6 dietitians

The prescription is one part. Here is the rest, in Parker.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Parker, CO, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Lauren Anderson, RDN
RD
Registered dietitian
8676 Thunderbird Rd
Call 720-270-8611NPI 1962389049
Laura Becker, RD
RD
Registered dietitian
18275 Cottonwood Dr
Call 608-449-2507NPI 1205510252
Christy Beyerly, RD CDE
RD
Registered dietitian
9395 Crown Crest Blvd
Call 303-269-4000NPI 1033125794
Jennifer Bolton, RDN, IBCLC
RD
Registered dietitian
11983 Song Bird Hills St
Call 303-437-6961NPI 1255101440
Laura Brown, RD
RD
Registered dietitian
8442 Prairie Clover Way
Call 805-340-0302NPI 1669118022
Joanna Cummings, MS, RD-AP, CNSC CSSD
RD
Registered dietitian
10100 S 20 Mile Rd
Call 303-204-6444NPI 1114329257

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Danielle Abrahams, CCN
NUTRITIONIST
Nutritionist
12031 Blackwell Way
Call 720-587-7778NPI 1538668876
Mary Beth Gudewicz, CNTP
NUTRITIONIST
Nutritionist
21845 Whirlaway Ave
Call 720-771-4624NPI 1376961417
Kelsey Martin, CNS, LDN
NUTRITIONIST
Nutritionist
10633 Clarke Farms Dr
Call 208-863-0530NPI 1821970609
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program and the SURPASS diabetes program, including the SURPASS-2 head-to-head against semaglutide. Figures are means at each trial's primary endpoint.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
HbA1c reduction (T2D)
−1.8 to −2.6%
SURPASS program[4]
vs. semaglutide 1 mg
Superior
SURPASS-2, HbA1c + weight[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average tirzepatide weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most Tirzepatide side effects are stomach and gut effects.

In Zepbound's weight trials at 5 to 15 mg, the most common side effects were nausea (25 to 29%), diarrhea (19 to 23%), constipation (11 to 17%), and vomiting (8 to 13%). Mounjaro's diabetes trials showed lower rates at the same doses.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[1]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 29%
mild
Lowest on Mounjaro 5 mg, highest on Zepbound 10 mg
Diarrhea
12 to 23%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Reported in Mounjaro's diabetes trials
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

What Tirzepatide costs, by how you pay.

The price you pay depends on your insurance plan, your diagnosis, and how you buy. Manufacturer self-pay programs cost far less than pharmacy retail. Here are the ranges.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Eli Lilly self-pay and savings pages.

Self-pay and savings card prices checked . Retail averages from May 2026.

Tirzepatide monthly cost by how you pay
Zepbound, pharmacy retail$1,000 to $1,300per monthBrand-name retail average, May 2026[6]
Zepbound, LillyDirect self-pay$299 to $699per monthKwikPen by dose: 2.5 mg $299, 5 mg $399, 7.5 mg $499, 10 to 15 mg $699. The $449 offer on 7.5 to 15 mg applies to the first purchase and to refills within 45 days. Vials start at $299
Mounjaro, pharmacy retail$1,000 to $1,200per monthBrand-name retail average, May 2026[6]
Commercial insurance (T2D)$25 to $250per month copayUsually covered for diabetes with prior authorization
Commercial insurance (weight)Often deniedZepbound is on-label but frequently requires PA
Medicare Part D$0 to $100per monthType 2 diabetes covered. Zepbound KwikPen for weight management is $50 a month through the Medicare GLP-1 Bridge, Jul 2026 to Dec 2027[5]
Manufacturer savings cardas low as $25per monthCommercial insurance only; eligibility limits apply
Find Tirzepatide providers in Parker

Physicians from the federal NPI registry. Ask each office whether it prescribes Tirzepatide.

Tirzepatide in other states

Physicians from the federal NPI registry in the states we cover. Ask each office whether it prescribes Tirzepatide.

Related GLP-1 research
§ 09Frequently asked: Tirzepatide in Colorado

The questions people ask before they book.

Answers reviewed by the glp·helper Medical Team. Citations link to primary sources, never marketing copy.

Tirzepatide is the active ingredient in two Eli Lilly brands: Mounjaro and Zepbound. No generic tirzepatide is FDA-approved in the US. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. They share an active ingredient but carry different approved indications, and insurers treat them as separate products.[1]